Publication: Curr Opin Genet Dev. 2019 Mar 4;54:7-11. doi: 10.1016/j.gde.2019.02.003
Authors: Tiriac H, Plenker D, Baker LA, Tuveson DA.
Despite recent advances in the treatment of cancer, pancreatic ductal adenocarcinoma (PDAC) still retains the worst survival rate of common malignancies. Late diagnosis and lack of curative therapeutic options are the most pressing clinical problems for this disease. Therefore, there is a need for patient models and biomarkers that can be applied in the clinic to identify the most effective therapy for a patient. Pancreatic ductal organoids are ex-vivo models of PDAC that can be established from very small biopsies, enabling the study of localized, advanced, and metastatic patients. Organoids models have been applied to pancreatic cancer research and offer a promising platform for precision medicine approaches.
Science Translational Medicine 09 Oct 2019: Vol. 11, Issue 513, eaay2574 DOI: 10.1126/scitranslmed.aay2574
Commun Biol. 2019 Feb 25;2:78. doi: 10.1038/s42003-019-0305-x. eCollection 2019.
Ann Surg Oncol. 2019 Jan;26(1):139-147. doi: 10.1245/s10434-018-7008-2. Epub 2018 Nov 9.
Nature 561, S48-S49 (2018); doi: 10.1038/d41586-018-06708-3
Human Molecular Genetics, Volume 27, Issue R2, 01 August 2018, Pages R99–R107
Nature Reviews Cancer, volume 18, pages407–418 (2018)
Subscribe to our newsletter
Stay up-to-date on the latest advancements in 3D cell culture technology